Location: Washington, D.C.
Mission: To provide a leading, innovative, open, balanced marketplace of ideas for education and discourse across the field of global food and drug law that enables key stakeholders to inform, debate, and shape the evolution of public policy and regulation.
The Food and Drug Law Institute (FDLI) is a non-profit membership organization committed to providing timely information, analysis, and a platform for discussion on the latest issues in FDA regulated products, including food, drugs, animal drugs, biologics, diagnostics, dietary supplements, cosmetics, medical devices, and tobacco. FDLI provides an innovative and open forum that enables key stakeholders to inform, debate, and shape the evolution of public policy and regulation. FDLI engages legal and regulatory professionals with an interest in FDA regulated products, at member manufacturers, suppliers, distributors, law firms, service organizations, and nonprofits. Individual memberships are available to government employees, academics, solo practitioners, and students.
The Food and Drug Law Institute (FDLI) offers a diverse array of conferences, webinars, and meetings addressing the latest on legal, regulatory, compliance, policy, marketing, and economic issues in the food and drug space. FDLI also offers in-depth introductory courses on food, drug, device, and tobacco law and regulation.
“FDLI’s strength is its broad membership and its multi-stakeholder approach,” said Amy Comstock Rick, Esq., president & CEO of FDLI. “As industry, health-related governmental agencies, and life sciences organizations move towards cross-disciplinary approaches to problem solving, FDLI serves as a venue for policy analysis, debate, and education that supports coordinated efforts.”
The cornerstone of FDLI’s professional development offerings is the FDLI Annual Conference, to be held May 5-6 in Washington, D.C. The conference features presentations by professionals with significant experience, influence, and expertise, and provides a critical opportunity for practitioners in all sectors and roles to network and learn about and discuss the latest regulatory developments.
Conference highlights include FDA’s 2016 strategic priorities, for every product category, reported on by key agency leadership, as well as insights from experts representing other federal agencies, industry, the private bar, patient and consumer advocates, consulting organizations, and academia.
“Serving as a place to find and learn from professionals who are looking at the same issues, but from a very different perspective, is a part of FDLI’s mission that will grow substantially in the coming years,” Comstock Rick shared. As the community continues to emphasize patient engagement in all aspects of therapy development and access, knowing the legal barriers and opportunities will be key to the patient community being a fully engaged participant. “FDLI will help fill that gap,” she added.
FDLI also publishes key reference resources and periodicals.The periodicals include the bimonthly Update magazine, focusing on the latest trends in food and drug law, and the Food and Drug Law Journal, the premier scholarly quarterly in the field published in conjunction with Georgetown University Law Center. The Food and Drug Policy Forum, published monthly, offers diverse perspectives on cutting-edge policy issues and contributes to policy debates.
As a member of Research!America, FDLI shares a common interest to advance medical and health innovation, and provides a neutral space for dialogue among the multiple stakeholders in our complex and rapidly evolving field.
To learn more, please visit www.fdli.org.